Allspring SMID Core ETF ASCE 深 沪
已收盘 12-19 16:00:00 美东时间
27.77
+0.313
+1.14%
华盛通- 最 高27.78
- 今 开27.68
- 成交量 6426股
- 最 低 27.68
- 昨 收 27.457
- 总市值 3557.34万
- 52周最高 27.90
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 24.12
- 委 比 0.00%
- 总股本 128.10万
- 历史最高 27.90
- 量 比 0.71
- 振 幅 0.36%
- 历史最低 24.12
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gilead fails late-stage trial for Trodelvy in first-line breast cancer
Gilead Sciences (GILD) announced on Friday that a Phase 3 trial for its FDA-approved antibody-drug conjugate Trodelvy failed in a Phase 3 trial, which tested it as a first-line option for certain pati...
11-07 22:14
Amarin To Present New Data Highlighting VASCEPA's Cardiovascular Benefits And EPA's Anti-Inflammatory, Antioxidant Mechanisms At AHA 2025
Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana.
11-03 21:41
Reported Sunday, Gilead Sciences' Phase 3 ASCENT-03 Study Shows Trodelvy Cut Risk of Disease Progression Or Death By 38% Versus Chemotherapy In First-Line Metastatic Triple-Negative Breast Cancer
– Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine –– With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First and Only ADC to be a
10-20 15:47
KBR secures $98.7M U.S. Space Force task order
KBR (NYSE:KBR) received a $98.7 million, three-year task order from the U.S. Space Force to build a testing and training environment in Colorado Springs. The project, called Design Implementation for ...
10-16 18:21
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.
09-18 03:15
J&J studies find icotrokinra more effective than deucravacitinib for psoriasis
Johnson & Johnson (NYSE:JNJ) said that data from late-stage studies showed that its oral medication, icotrokinra, was more effective compared with Bristol Myers' (BMY) deucravacitinib (Sotyktu) for mo...
09-17 21:44
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis
Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients.
09-10 03:06
Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug
Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and effective in the long term, based on data from a Phase 3 trial for patients ...
09-09 19:08
ISS National Lab's Orbital Edge Accelerator Program Selects Six Startups
Each startup to receive up to $500,000 in investment and future research opport...
07-17 03:58
Allspring Launches 3 Active ETFs, Including 1 For Tax-Free Income
Allspring's three new actively managed ETFs offer exposure to quality stocks and ultra-short municipal bonds with tax-free income potential.
07-09 03:39
